When was LumaBridge founded?

LumaBridge was founded in 2013 and raised its 1st funding round 9 years after it was founded.

Where is LumaBridge located?

LumaBridge is headquartered in San Antonio, United States. It is registered at 1305 E HOUSTON ST,SAN ANTONIO,TX,78205.0,15.

Is LumaBridge a funded company?

LumaBridge is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Aug 23, 2022.

When was the latest funding round of LumaBridge?

LumaBridge's latest funding was a $***** Seed round on Aug 23, 2022, with participation from 1 investor.

Where does LumaBridge rank among its competitors?

LumaBridge ranks 13th amongst 42 active competitors, of which 5 are funded. It stands 11th in terms of total funding among its competitors.

Who are the top competitors of LumaBridge?

LumaBridge's top competitors include Oncodesign, Orakl Oncology and TD2. Among them, LumaBridge secured the most recent funding round in August, 2022.

LumaBridge - 2026 Company Profile, Team, Funding & Competitors

LumaBridge is an acquired company based in San Antonio (United States), founded in 2013 by George Peoples. It operates as a Provider of oncology clinical research, regulatory affairs, and data management services. LumaBridge has raised an undisclosed amount in funding. The company has 42 active competitors, including 5 funded and 6 that have exited. Its top competitors include companies like Oncodesign, Orakl Oncology and TD2.

Company Details

LumaBridge is an oncology-focused CRO, designing and executing innovative clinical trial solutions for emerging biopharma companies. It acts as a strategic development partner, combining academic, scientific, and commercial perspectives to deliver oncology CRO services that exceed expectations—and ultimately advance novel immunotherapies to benefit patients.

Website: lumabridge.com
Social
Registered Address: 1305 E HOUSTON ST,SAN ANTONIO,TX,78205.0,15

Key Metrics

Founded Year

2013

Location

San Antonio, United States

Stage

Acquired

Latest Funding Round

Seed, Aug 23, 2022, $*****

Investors

Summit Partners

Ranked

13^th among 42 active competitors

Similar Companies

Oncodesign & 49 more

Exit Details

Acquired by Avance Clinical (Jan 07, 2026)

View LumaBridge's full profile

LumaBridge is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
LUMABRIDGE, LLC CIN: 32069204553 , United States, Active	Dec 16, 2018	-	-	-

LumaBridge got acquired by Avance Clinical on Jan 07, 2026.

Click here to take a look at LumaBridge's acquisition in detail

LumaBridge has raised funding over 1 round. Its latest funding round was a Seed round on Aug 23, 2022 for $*****. 1 investor participated in its latest round. LumaBridge has 1 institutional investor.

Here is the list of recent funding rounds of LumaBridge:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 23, 2022	8623490	Seed	2132619	3123848	8829561	7143042

Access funding benchmarks and valuations. Sign up today!

View details of LumaBridge's funding rounds and investors

The founders of LumaBridge is George Peoples. Dave Boyle is the CEO of LumaBridge.

Here are the details of LumaBridge's key team members:

George Peoples: Founder of LumaBridge.
Dave Boyle: CEO of LumaBridge.

View details of LumaBridge's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of LumaBridge include Oncodesign, Orakl Oncology and TD2. Here is the list of Top 10 competitors of LumaBridge, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Oncodesign 1995, Dijon (France), Acquired	Provider of preclinical assessment services for anticancer therapies	$4.71M	Credit Mutuel Equity, Banque de Vizille & 2 others	46/100
2nd	Orakl Oncology 2023, Villejuif (France), Seed	Orakl Oncology is a precision oncology start-up that enables the emergence of rare oncology by connecting patient tumors to the world's 3rd best cancer center.	$14.7M	Bpifrance, Verve Ventures & 3 others	45/100
3rd	TD2 2003, Phoenix (United States), Acquired	Provider of oncology-based preclinical and clinical development services	-	-	37/100
4th	Lytica Therapeutics 2019, Cambridge (United States), Series A	Developer of therapeutic drugs	$5.82M	CARB-X	33/100
5th	AHG 2021, China, Public	Provider of cancer therapy development services	-	-	31/100
6th	Exigent Research 2022, Stockton (United States), Unfunded	Provider of clinical cancer research access and care through partnerships with independent oncology clinics.	-	-	28/100
7th	Misvik Biology 2014, Turku (Finland), Funding Raised	Provider of precision oncology contract research and toxicology research services	-	European Union	25/100
8th	ONCOtracker 2014, West Hollywood (United States), Seed	Developer of immune assays for the diagnosis of cancer	$1.3M	-	25/100
9th	ProQinase 2001, Freiburg im Breisgau (Germany), Acquired	Contract research company for cancer drug discovery	-	-	25/100
10th	Orange Grove Bio LLC 2019, New York City (United States), Series B	Provider of preclinical development services	$16.6M	Catalytic Impact Foundation, AlleyCorp	25/100
13th	LumaBridge 2013, San Antonio (United States), Acquired	Provider of oncology clinical research, regulatory affairs, and data management services	-	Summit Partners	40/100